Interferon alpha-2a biosimilar - Amega Biotech

Drug Profile

Interferon alpha-2a biosimilar - Amega Biotech

Alternative Names: Interferon Alfa-2a biosimilar - Amega Biotech

Latest Information Update: 23 Aug 2013

Price : $50

At a glance

  • Originator Amega Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis C; Kaposi's sarcoma

Most Recent Events

  • 14 Aug 2013 Investigation in Kaposi's sarcoma (AIDS-related) in Argentina (Parenteral)
  • 14 Aug 2013 Investigation in Hepatitis C in Argentina (Parenteral)
  • 14 Aug 2013 Investigation in Hairy cell leukaemia in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top